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Complement is a major element of the innate immune
response and also serves to link innate and adaptive
immunity. It is an ancient immunological defence system
that is thought to have evolved over 700 million years ago
and components have been identified in all vertebrate
classes (Zarkadis et al., 2001). Complement comprises
over 30 serum and membrane-bound proteins which, when
activated, form a cascade of reactions contributing to the
elimination of invading microorganisms. Three pathways
of activation exist, the classical, lectin, and alternative
pathways (outlined in Fig. 1A and reviewed in Walport,
2001), all of which invoke several responses capable of
controlling or eliminating infection. This overview will
focus on the interaction of viruses with complement,
highlighting the protective role of complement against
viral infection, the mechanisms used by viruses to evade
the effects of complement and the ways in which some
viruses can exploit complement to enhance infection. It
does not aim to provide a comprehensive analysis but
rather an overview of the interaction between viruses and
complement. Our intention is to emphasise the growing
recognition of the importance of complement to virus
biology, revealed through the increasing number of viruses
known to have either active or passive (or both) strategies
of complement regulating activity.Regulation of complement activity
Complement activation can be potentially damaging to
host cells and must therefore be tightly regulated. For this
reason, activated components have very short half-lives
and are regulated by a large family of host plasma and
membrane-bound proteins that are involved in the physi-0042-6822/$ - see front matter D 2004 Published by Elsevier Inc.
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cade. Examples of mammalian complement control
proteins are given in Table 1. Complement regulation is
based upon three principle mechanisms: (i) accelerated
dissociation of the enzymes that cleave C3 and C5, so-
called convertase complexes, which mediate the cascade of
complement activation; (ii) enzymatic cleavage to inacti-
vate components; and (iii) inactivation following irrevers-
ible binding of inhibitors. Host proteins involved in
regulating complement include C1 inhibitor, CD59, and a
group of proteins known as regulators of complement
activation (RCA) (reviewed in Morgan and Harris,
1999). RCA proteins contain structural motifs known as
short consensus repeats (SCRs), with each SCR compris-
ing 60–70 amino acids and a conserved motif of di-
sulphide-linked cysteines and several hydrophobic resi-
dues. RCA proteins only regulate complement components
C3b and C4b. Other resistance mechanisms adopted by
nucleated cells include the expression of ecto-proteases on
their surface that can inactivate complement components
by cleavage. Nucleated mammalian cells can also avoid
lysis by the terminal complement membrane attack com-
plex (MAC; see below) through shedding or endocytosis
of vesicles enriched in MAC components (Carney et al.,
1985, 1986; Scolding et al., 1989).Complement activation during virus infection
Virus infection can activate all three pathways of the
complement cascade (see Fig. 1). The classical pathway is
activated by the binding of the complement component C1q
to antibody–antigen complexes. This activation can also be
achieved by C1q binding directly to the glycoproteins of
some viruses, in the absence of specific antibodies. These
viruses include human cytomegalovirus (HCMV) (Spiller
and Morgan, 1998) and certain retroviruses (Cooper et al.,
1976; Solder et al., 1989), such as human T cell lympho-
tropic virus (HTLV) (Ikeda et al., 1998). The lectin pathway
is antibody-independent and is activated upon the interaction
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drates. This pathway has been implicated in the control of
several viral infections, including hepatitis B virus (HBV)
(Wang, 2003) and influenza (Hartshorn et al., 1993; Thielens
et al., 2002). The third pathway, the alternative pathway, was
originally defined as the antibody-independent activation
pathway (as the lectin pathway was not discovered until
some decades later). Activation of the alternative pathway is
triggered by the continual low-level spontaneous release of
the internal thioester bond of C3 to form a tightly regulated
C3 convertase. This C3 convertase may either exist in the
fluid phase or be attached to the cell surface, if the
spontaneous events occur near cells. More importantly,
further activation of the alternative pathway only occurs
on a foreign or ‘‘activating’’ surface that is determined by a
lack of factor H binding to the surface. Factor H binding and
regulation of the alternative pathway depends on the addi-
tion of sialic acid to carbohydrates found on the cell surface,
which can be decreased following infection by some
viruses.
Complement activation by all three pathways results in
several effector functions that contribute to virus inactiva-
tion and elimination. These functions include opsonisation
of virions by complement components promoting phagocy-
tosis, virolysis by the MAC, and enhancement of several
arms of the immune response through the production of
anaphylatoxins and chemotactic factors. Each of these
effector functions is discussed below.
Virus opsonisation
Complement components C1q, C3b, and C4b can bind to
the virion surface forming a protein coat. This opsonisation
can neutralise viral infection in a variety of ways. Phago-
cytic cells have surface receptors that recognise and bind to
C1q, C3b and C4b, promoting uptake and destruction of
virions covered with these components (reviewed in Hannan
et al., 2002; Krych-Goldberg and Atkinson, 2001; McGreal
and Gasque, 2002). Covalent attachment of C3b and C4b to
the virion surface may also prevent viral interaction with
receptors, uncoating and entry into host cells. Indeed,
coating of several viruses, including human immunodefi-
ciency virus (HIV), with C3 has been shown to functionally
inactivate the virus in vitro and in vivo (Sullivan et al.,
1998). Aggregation of viral particles due to the binding of
multivalent complement components, such as C1q and
antibodies, can neutralise virus infectivity and also promote
phagocytosis via Fc receptors.
Virolysis
Although opsonisation itself can inactivate infectious
virions, enveloped viruses are also susceptible to lysis by
the MAC. The amphipathic complement components from
C5b to C9 combine and insert into the viral envelope to
form a transmembrane channel. This channel results in abidirectional flow of ions and macromolecules, which dis-
rupts viral integrity and eventually leads to osmotic lysis
and irreversible loss of viral activity. Alphaviruses, corona-
viruses, herpesviruses, and retroviruses are some that are
susceptible to killing by the MAC (Mochizuki et al., 1990;
Spear et al., 1993; Vasantha et al., 1988).
Anaphylatoxin and chemotaxin production
Enzymatic cleavage of complement components C3,
C4, and C5 during complement activation results in the
production of low molecular weight, biologically active
peptides: the anaphylatoxins C3a, C4a, and C5a, respec-
tively (see Fig. 1). Overall, these anaphylatoxins activate
many cell types, concomitant with the wide range of cells
on which their receptors are expressed (reviewed in Ember
and Hugli, 1997; Kohl, 2001). They mediate many inflam-
matory responses including smooth muscle contraction,
enhanced vascular permeability, release of vasoactive
amines, and induction of lysosomal enzyme release. C5a
is the most potent anaphylatoxin, functioning as a chemo-
attractant for leukocytes and neutrophils, recruiting them to
the region of complement activation and inflammation.
C3a may also act as a chemotactic factor for eosinophils
and T cells.
Other effects of complement
Complement can play an important role in the induc-
tion of humoral immunity against viruses. C3b and iC3b
(see Fig. 1B-II) opsonised virions can bind to follicular
dendritic cells (FDC) in lymph nodes via the complement
receptors CR1 and CR3, which serves to enhance viral
antigen presentation to B cells. C3dg (see Fig. 1B-II)
combined with viral antigen can also induce cross-linking
of the B cell antigen receptor and CR2 on the B cell
surface. Indeed, it has been shown that mice deficient in
various complement components fail to develop normal
memory responses to herpes simplex virus (HSV) (Da
Costa et al., 1999). Furthermore, the antigenicity of the
HIV envelope glycoproteins encoded by env (and other
viral antigens) was augmented by creating a DNA vaccine
for evaluation in mice, whereby env was fused to the
human or murine genes encoding C3d (Green et al.,
2001).Viral infections associated with complement deficiencies
Hypocomplementaemia is the medical term used to
define a condition where a component of complement is
lacking or is reduced in concentration. Although deficien-
cies in components of complement are rare, patients with
hypocomplementaemia have been shown to be more sus-
ceptible to infection and disease by certain viruses. For
example, a positive correlation between hepatitis C virus
Table 1
Mammalian complement control proteins
Regulator Distribution Function
C1-inh soluble prevents spontaneous activation
of C1 and inactivates C1 on
surfaces
C4-bp* soluble accelerates decay of classical
pathway C3/C5 convertase;
factor I cofactor for degradation
of C4b
Factor H* soluble accelerates decay of alternative
pathway C3/C5 convertase;
factor I cofactor for degradation
of C3b
Factor I soluble cleaves C3b and C4b to inactive
fragments when bound to a
regulatory cofactor
CR1 (CD35)* cell-bound accelerates decay of classical
and alternative C3/C5 convertase;
factor I cofactor for degradation
of C3b and C4b
MCP* (CD46) cell-bound cofactor for the cleavage of
C3b and C4b by factor I
DAF* (CD55) cell-bound accelerates decay of C3/C5
convertases
CD59 cell-bound prevents MAC formation
C1-inhibitor (C1-inh), C4 binding protein (C4-bp), factor H, and factor I are
all soluble proteins that regulate the early stages of complement activation.
Complement receptor 1 (CR1), membrane cofactor protein (MCP), and
decay accelerating factor (DAF) are membrane-bound proteins that act at
the level of C3, a central component of the complement cascade. CD59 is a
cell surface protein that prevents formation of the terminal membrane attack
complex (MAC) involved in membrane disruption and cell lysis. RCA
proteins are indicated by an asterisk.
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demonstrated. Furthermore, the severity and frequency of
HSV reactivation and nonresponsiveness to HBV vaccina-
tion have been linked to C4 deficiency (Hohler et al.,
2002; Seppanen et al., 2001).Fig. 1. Activation pathways of complement (A) and their regulation (B). (A) Three
all three pathways is the formation of C3 and C5 convertase enzyme complexes. T
C3b. The latter protein forms the C5 convertase, which cleaves C5 to C5a (anaph
pore, known as the membrane attack complex (MAC). (I) Activation of the clas
regions of antigen-bound IgG and IgM. This binding induces the autolytic cleavage
cleaves C4. The resulting C4b then binds covalently to the cell surface enabling C2
C3 convertase, C4b2a. (II) The lectin pathway is triggered in an identical manner
carbohydrate that activates the MBL-associated serine proteases (MASP), which ar
three separate MASPs have been identified, only MASP-2 can form a C3 conver
continually active, but only amplifies on an activating surface because of insuffic
other two pathways. The alternative pathway is triggered by the constant low-le
internal thioester bond. The resulting hydrolysed C3 (either fluid phase or cell-boun
protease factor D (fD). This complex then generates more C3b and results in the fo
stabilised by the association of the serum protein properdin (not shown). (IV)
noncovalently with C6. This association enables a loose interaction with the m
association of C7 and C8 that causes insertion of the complex into the membrane
further incorporation of 12–16 molecules of C9. (B) Complement is regulated by s
accelerate the decay of the C3 convertases, in many cases, (II) subsequently indu
convertase to fragments that can no longer bind C2 (see AI and AII) or fB (see
association with either the terminal complement components (CD59) or the in
subsequent removal of the C1rs protease complex.Viral evasion of complement
Viruses have evolved numerous mechanisms to evade the
destructive effects of complement. They include passive
strategies, for example, where cellular complement regula-
tory proteins may be incorporated into the envelope of
viruses as they bud from the cell surface, and active strate-
gies in which certain viruses encode their own complement
regulatory proteins. Some of these mechanisms will be
discussed (see also Favoreel et al., 2003; Lee et al., 2003).
Incorporation of host complement regulatory proteins into
virus envelopes
The incorporation of host RCA proteins and CD59
during egress from the host cell is a mechanism utilised
by some enveloped viruses to protect the cell-free virion
from complement-mediated attack. The exact mechanism
for this process is unknown but may involve viral budding
from certain regions of the cell surface enriched with
complement regulatory proteins, such as lipid rafts. Various
isolates of HIV can be immunocaptured by anti-membrane
cofactor protein (MCP), anti-decay accelerating factor
(DAF), and anti-CD59 antibodies, and incorporation of all
three proteins has been demonstrated to protect virions from
complement-mediated lysis (Saifuddin et al., 1997). Vac-
cinia virus (VV), HTLV, and HCMV are other examples of
viruses that can incorporate host complement regulatory
proteins into their envelope, affording protection against
complement (Spear et al., 1995).
Prevention of complement activation by antibody–antigen
complexes and viral Fc receptors
Some viruses, including psuedorabies virus (PRV), a
swine a-herpesvirus, can shed or internalise antibody–separate routes of complement activation are depicted (I– III). Common to
he C3 convertase (C4b2a or C3bBb) cleaves C3 into C3a (chemotaxin) and
ylatoxin) and C5b. The production of C5b enables the formation of a lytic
sical pathway results from the binding of C1q to two immunoglobulin Fc
of C1r and the subsequent cleavage of C1s to its active from. Activated C1s
to bind. C1s then cleaves C2 complexed with C4b, generating the classical
except that it is recognized by the mannan-binding lectin (MBL) of foreign
e capable of cleaving C4 and C2 to create the C3 convertase, C4b2a. While
tase (reviewed in Schwaeble et al., 2002). (III) The alternative pathway is
ient regulation. It also serves as a C3 convertase amplification loop for the
vel spontaneous cleavage of C3 that occurs by nonspecific release of the
d) then forms a complex with factor B (fB), which is itself cleaved by serum
rmation of the alternative pathway C3 convertase (C3bBb), which is further
C5b, generated by any of the previous activation pathways, associates
embrane surface, which is strengthened by the subsequent noncovalent
. The full membrane attack complex consists of a lytic pore formed by the
everal mechanisms (see also Table 1): (I) surface-bound and serum proteins
cing factor I (fI) cleavage of the covalently attached components of the C3
AIII). (III) Conversely, other regulators act through ‘‘suicide’’ irreversible
itial C1qrs complex of the classical pathway (C1 inhibitor) resulting in
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ment activation or phagocytosis (Van de Walle et al., 2003).
Other viruses [HSV, varicella-zoster virus (VZV), HCMV]
or virus-infected cells express Fc-like receptors that have
been proposed to bind the Fc portion of nonspecific IgG in a
conformation that sterically hinders access of specific anti-
virus antibody or prevents complement activation (Antons-
son and Johansson, 2001; Dowler and Veltri, 1984; Litwin
and Grose, 1992). In this regard, binding of nonimmune IgG
to HSV-1-infected cells has been shown to protect them
against complement-mediated lysis and to protect HSV-1
virions from antibody neutralisation (Dowler and Veltri,
1984). HIV has been reported to impair complement-medi-
ated phagocytosis of infected cells, possibly by interfering
with downstream signalling events (Kedzierska et al., 2003).
Virus-encoded proteins
The larger DNA viruses have the genomic capacity to
encode proteins that have complement regulatory activity
and several of them have been characterised extensively.
Many of the proteins have been identified based on their
homology to cellular complement regulatory proteins, but
some, including the HSV-1 and -2 gC glycoproteins, show
no homology to cellular proteins, and thus may regulate
complement by different mechanisms (see below).
i. Host complement control protein homologues
Many members of the herpesvirus and poxvirus families
encode complement control protein homologues that are
known to inhibit the antiviral effects of complement by
different mechanisms. Three g-herpesviruses, Kaposi’s sar-
coma associated herpesvirus (KSHV), herpesvirus saimiri
(HVS), and murine g-herpesvirus 68 (MHV68), encode
proteins (KCP, CCPH, and MHV68-RCA, respectively)
with homology to DAF and MCP, all of which inhibit
complement activation (Fodor et al., 1995; Kapadia et al.,
1999; Spiller et al., 2003b). KSHV KCP comprises three
protein isoforms that are thought to be produced by alter-
native splicing and they all regulate complement activation
(Spiller et al., 2003b). KCP can prevent cell surface depo-
sition of C3b, enhance the decay of the classical pathway C3
convertase, and act as a cofactor in a factor I-mediated
cleavage reaction (see Fig. 1B-II; Mullick et al., 2003;
Spiller et al., 2003a, 2003b). The HVS CCPH protein shows
similar activity to KCP, in that it inhibits C3b deposition and
C3 convertase activity (Fodor et al., 1995). A second,
distinct complement regulatory protein encoded by HVS,
HVS15, is thought to control complement activity by block-
ing formation of the terminal MAC (Albrecht et al., 1992).
The MHV68 RCA protein can inhibit complement
activation by the classical and alternative pathways (Kapa-
dia et al., 1999). Recently, an MHV68 RCA deletion
mutant was created to evaluate the contribution of this
complement control protein to viral pathogenesis in vivo
(Kapadia et al., 2002). The results indicated that theMHV68 RCA protein is required for full virulence in acute
and chronic infection and that the attenuated phenotype of
the mutant could be reversed by deletion of host C3.
Complement was also shown to have a role in regulating
latency. Such findings demonstrate the potential importance
of complement in g-herpesvirus infection and that these
viruses have evolved successful strategies for evading
complement.
Some of the poxviruses such as cowpox, variola, and VV
encode functional homologues of complement control pro-
teins, of which the VV complement control protein (VCP)
has been most extensively characterised. VCP can accelerate
the decay of classical and alternative pathway convertases
and acts as a cofactor for factor I-mediated cleavage of C3b
and C4b (McKenzie et al., 1992; Sahu et al., 1998). VCP is
secreted from infected cells, contributes to virulence in
animal models, and can prevent antibody-complement de-
pendent neutralisation of VV (Isaacs et al., 1992).
ii. Complement control proteins lacking homology to
cellular proteins
The gC glycoproteins of HSV-1 and -2 are the only
characterised viral complement control proteins lacking any
homology to host complement regulatory proteins. HSV-1gC
was the first viral protein identified as binding complement
(Friedman et al., 1984; Fries et al., 1986). Although the gC
glycoproteins of HSV-1 and -2 are highly homologous to one
another, they demonstrate significant differences in their
ability to regulate complement. HSV-1 gC can accelerate
the decay of the alternative pathway convertase and protects
HSV-1 against the complement activities of this pathway
(Hung et al., 1994). An HSV-1 gC mutant incapable of
binding complement has been shown to have reduced path-
ogenicity in an animal model of infection (Lubinski et al.,
1998). HSV-2 gC does not accelerate the decay of the
alternative pathway convertase but does provide protection
against complement-mediated neutralisation. However, com-
pared to the HSV-1 gC protein, HSV-2 gC demonstrates poor
complement regulatory activity. Epstein–Barr virus (EBV)
also has complement regulatory activity (Mold et al., 1988),
but does not encode for any proteins showing homology to
host complement regulatory proteins, highlighting that much
remains to be understood about these viral proteins.
Other mechanisms
Up-regulation of host RCA on the surface of infected
cells has been demonstrated for HCMV, where MCP and
DAF expression is up-regulated up to 8-fold (Spiller et al.,
1996). Although the mechanism for this regulation has not
been determined, up-regulation of DAF has been shown to
increase resistance of these infected cells to complement
mediated lysis. However, the mechanism of murine CMV
up-regulation of MCP has been determined to depend on a
cis-acting virus-responsive promoter element in the MCP
promoter (Nomura et al., 2002).
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components to their surface or to the surface of infected
cells, in addition to incorporating RCA proteins in their
envelope. HIV can bind factor H to its surface, through an
interaction with the gp41 and gp120 glycoproteins (Stoiber
et al., 1995). This binding has been shown to significantly
protect virions from the effects of complement (Stoiber et
al., 1996) and promotes the degradation of bound C3b to
iC3b that enhances the ability of HIV to interact with FDC.
Sindbis virus is thought to incorporate host sialic acids
into its envelope during budding. The amount of sialic acid
on cells infected with this virus positively correlates with
resistance to complement, presumably through the ability to
recruit and bind factor H (Hirsch et al., 1981). Mimicking
host surfaces in this way may help avoid complement
activation by the alternative pathway.
Latency may also serve as a mechanism to evade comple-
ment by preventing the expression of viral antigens on the cell
surface that could target the cell for complement-mediated
destruction. However, viruses undergoing latent infection
must have the ability to evade complement attack once
reactivated, as certain herpesviruses seem to do (see above).Viral exploitation of complement to enhance infection
Many viruses can exploit the complement system to
promote infection, either by direct binding to complement
receptors (CR) to gain entry to host cells or indirectly
through complement-opsonised virus interactions.
Direct binding to complement receptors and regulators
CR are expressed on many tissues and cells, including
neutrophils, FDC, B cells, and macrophages. They have an
important role in clearing immune complexes, as well as in
neutrophil function. It is well established that EBV gains
entry to B cells and endothelial cells through interactions
between the viral gp350/220 proteins and complement re-
ceptor CR2 (Fingeroth et al., 1984), although other receptors,
such as certain integrins, have also been shown to be involved
(Tugizov et al., 2003). Kinetic studies have indicated that
gp350/220 has higher affinity for CR2 than host C3 frag-
ments and would effectively surpass host CR2–C3dg bind-
ing (Moore et al., 1989). Complement regulators are also
targets for viral binding. MCP has recently been identified as
a receptor for group Badenoviruses, since non-permissive
cells were rendered susceptible to viral infection by expres-
sion of MCP (Gaggar et al., 2003; Segerman et al., 2003).
Human herpesvirus 6 (HHV-6) and measles virus (MV) both
use MCP as a cellular receptor, although they utilise different
domains of this receptor for binding (Greenstone et al., 2002).
Identification of MCP as the receptor for MV has led to the
development of a transgenic mouse model that has contrib-
uted to in vivo studies of viral pathogenesis (Horvat et al.,
1996; Rall et al., 1997). However, the primary MV receptor,signalling lymphocyte-activation molecule (SLAM) (Tatsuo
et al., 2000), is not part of the complement system. Never-
theless, the lack of SLAM in the central nervous system
(CNS) suggests that utilisation of MCP by MV may deter-
mine the development of the severe CNS complications
(subacute sclerosing panencephalitis) sometimes associated
with MV infections. Several other viruses, including many
enteroviruses, such as echovirus 7 and certain coxsackie
viruses, use DAF as a co-receptor (Bergelson et al., 1994;
Martino et al., 1998; Shafren, 1998; Spiller et al., 2000);
binding may not be sufficient to enable viral entry, but rather
serve to facilitate interactions with other accessory mole-
cules, hence the use of the term co-receptor. Closely related
picornaviruses that bind DAF have been shown to interact
with different SCRs of the DAF protein (Powell et al., 1999).
Indirect interactions between viruses and host cells
Coating of viral surfaces with complement components
may enhance infection for some viruses, including West
Nile virus, HTLV-1, and HIV, via the interaction of virus-
bound complement components with host CR (Cardosa et
al., 1983; Robinson et al., 1990; Saifuddin et al., 1995;
Stoiber et al., 1997). HIV either opsonised by complement
or immunocomplexed (complement fragments plus anti-
body) can associate efficiently with cells expressing CR,
including FDC, macrophages, monocytes, and B cells. This
association can facilitate infection of CD4-positive and -
negative cells. For example, infection could be promoted of
lymphocytes trafficking through lymphoid tissue by HIV
trapped on high-density CR expressed on FDC (Moir et al.,
2000). The anaphylatoxin C5a has also been shown to
increase the susceptibility of monocyte-derived macro-
phages to HIV infection (Kacani et al., 2001). Clearly, the
interactions between HIV and complement are complex and
a fine balance must exist between viral neutralisation and
enhancement of infection.Complement as a therapeutic target
Complement is an important mediator of inflammation
and inappropriate or prolonged activation can have unde-
sirable effects. Complement activation may contribute to
the pathology of many diseases, including ischaemia
reperfusion injury, adult respiratory distress syndrome,
and several autoimmune diseases (Makrides, 1998). For
this reason, many of human complement inhibitors are
currently being investigated as therapeutic agents, target-
ing various stages of the complement cascade. Several of
these inhibitors are currently in clinical trials (Holers,
2003; Smith and Smith, 2001) and many potential thera-
peutic agents have been identified to date. Indeed, the
range of viral proteins exhibiting complement-regulatory
activity at numerous stages of the complement cascade
could also be exploited in the search for novel agents to
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for complement components than host regulatory proteins,
as is the case with EBV binding to CR2 via the viral
gp350/220 glycoproteins (Moore et al., 1989). However,
the immunogenicity of such viral proteins would require
consideration.Viral vectors and gene therapy: role of complement
Viruses are currently the most common vector being
developed or being tested in gene therapy trials to correct
defective genes. Oncolytic viruses may also be utilised in
tumour therapy (Wakimoto et al., 2003). Viruses being
exploited for these technologies include retroviruses, adeno-
viruses, and HSV, and many preliminary studies have
reported encouraging results. However, the implementation
of gene therapy was severely and tragically compromised by
the death of a patient participating in a clinical trial for the
correction of a congenic liver defect. Death was due to
multiple organ failure, likely induced by a severe inflamma-
tory response to the adenovirus vector. Indeed, it has since
been demonstrated that treating isolated human plasma with
the same adenovirus serotype, and at concentrations match-
ing those reached during the trial, activates complement to
levels that could result in a vigorous inflammatory response
(Cichon et al., 2001). Hence, a comprehensive analysis of the
host immune response to viral vectors before their use in
clinical studies is needed. Such evaluation should consider
the ability of the host to eliminate the vector, rendering
therapy unsuccessful and the potential of the vector to induce
a severe inflammatory response, in which complement may
play a significant role.Concluding remarks
The importance of complement in controlling viral
infection is evident from the range of strategies utilised
by viruses to evade complement-mediated attack and from
the attenuated virulence of viruses with null mutations in
complement-control proteins. This review has highlighted
some of the interactions between viruses and complement.
Many of these interactions are complex. This is the case
with HIV, which can trigger all three pathways of comple-
ment activation and is susceptible to several of the resulting
effects, yet it has also evolved a range of strategies to evade
complement and can even utilise complement to enhance
infection. Many viral proteins are now known to be capable
of regulating complement activation and some may serve as
novel therapeutic agents for the treatment of complement-
mediated diseases. Most of these viral proteins have been
identified based on their homology to known cellular
regulators, but several have no known homology to cellular
proteins. Hence, not only may viral proteins have mecha-
nisms of complement regulation similar to those of cellularcomplement regulatory proteins, and provide potential tools
for dissection of complement biology, but some may also
represent classes of complement regulatory proteins yet to
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